Medicenna Therapeutics Corp (MDNAF)

Medicenna Therapeutics Corp (MDNAF) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $142M; returns 1 week +3.0%, 1 year -59.0%.

Medicenna Therapeutics Corp. is a clinical-stage Canadian biotechnology company focused on developing novel "Superkine" immunotherapies for cancer, autoimmune, and neuroinflammatory diseases. The company's core business model revolves around engineering interleukins (IL-2, IL-4, and IL-13) to create highly specific and potent cytokine-based therapies that modulate the immune system.

MDNAF financial model: income statement, cash flow and balance sheet